RNAscence

22/03/2024

The RNAscence presence is in Kyoto, Japan!

Our Co-Founder and Technology Expert, NTU Assoc Prof. Timothy Tan presented at TIDES Asia 2024, a global conference attended by experts from both biopharmaceutical companies and academia, coming from all around the world.

TIDES Asia is "the only event in Asia exclusively for experts in oligonucleotides, peptides, mRNA, genome editing, and delivery is a platform for exchanging strategies to accelerate the process of bringing molecules to market".

Prof Tim presented on the topic: "Clinically Effective Scar Treatment via a siRNA Transdermal Gene Silencing Technology: From Bench to Bedside and Beyond".
​
We are grateful for this platform to share with a wider audience the potential of our technology behind our product, Renectin Antiscar.

With every step we take to highlight our Research & Tech, we are encouraged by the growing adoption of RNA-based therapeutics for scar prevention in patients.

Visit https://informaconnect.com/asia-tides/ for more information.

27/02/2024

Unleashing “The Potential of RNA Therapeutics in Dermatology”

Our co-founders and co-inventors Chun Yong Yao, Timothy Tan, Tey Hong Liang, together with colleagues at National Skin Centre and Nanyang Technological University shine the spotlight on Ribonucleic acid (RNA) therapeutics.

In the article, they uncover the depths of RNA therapeutics in reaching undruggable targets with minimal off-target effects and high specificity for dermatological conditions.

RNAscence Biotech’s brainchild, Renectin Antiscar* (microneedle patch), is also developed on this trajectory and changing the face of scar care treatment for patients in this up and coming wave.

The commentary has been published by the Annals Singapore – Academy of Medicine.

Click on the following link https://annals.edu.sg/the-potential-of-rna-therapeutics-in-dermatology/ to read more and download a copy.

*Renectin Antiscar is now available for purchase at www.rnascence.com.

Ribonucleic acid (RNA) therapeutics involving, among others, microRNAs (miRNAs), small interfering RNAs (siRNAs) and/or antisense oligonucleotides (ASOs) hold

25/12/2023

Team RNAscence Biotech would like to wish one and all a Merry Christmas. May this festive season bring you lots of good cheer, love and the best of health!

As we wrap up 2023, we are grateful to each and every individual whom we have crossed paths with on our journey. Thank you to our corporate partners, patients and community for the trust and in embracing breakthroughs in skin therapeutics. We are excited for what's ahead and look forward to engaging you further.

Have a jolly Christmas season 🎅 and Happy New Year 🎊!

27/08/2023

We are humbled to be featured in The Straits Times and Lianhe Zaobao 联合早报 on our start-up and Renectin Antiscar – the world's first RNA-based scar prevention patch.

Read more about our thoughts & dedication to our network of support in our earlier post here https://www.facebook.com/100090634040902/posts/pfbid02pr8Qy7UB7GwpAHmam6v2DQZLKMJN6tq3eMgWdzFH1KiUGQXDiCBUdfXdtNNUJYfZl/?mibextid=cr9u03

For more information on RNAscence Biotech, Renectin Antiscar and online order, please visit our website https://www.rnascence.com/.

Thank you.

co11ab Novena, Nanyang Technological University, Singapore, Agency for Science, Technology and Research (A*STAR), National Healthcare Group (NHG), NTU Lee Kong Chian School of Medicine, NTUitive

27/08/2023

We are humbled to be featured in The Straits Times and Lianhe Zaobao 联合早报 联合早报 on our start-up and Renectin Antiscar – the world's first RNA-based scar prevention patch.

Since our product launch, we are heartened by the warm reception we have received across platforms hosted by institutions, agencies, industry players as well as in our engagements with clinicians who have thus formed our network of early adopters.

We are grateful that ST and Zaobao has strengthened our engagement with the community and allowed us to benefit people with the knowledge of Renectin Antiscar as a scar prevention solution to address their needs.

For more information on RNAscence Biotech, Renectin Antiscar and online order, please visit our website https://www.rnascence.com/.

See next post on our feature in Lianhe Zaobao.

Thank you.

co11ab Novena, Nanyang Technological University, Singapore, Agency for Science, Technology and Research (A*STAR), National Healthcare Group (NHG), NTU Lee Kong Chian School of Medicine, NTUitive

14/07/2023

Did You Know?

RNAscence Biotech is one of the inaugural batch of start-ups incubating at co11ab Novena!

What a momentous part of our inception and we are delighted to be at the heart of it all.

co11ab is a BioMedTech incubator, a tripartite alliance between the Nanyang Technological University Singapore (NTU), the A*STAR - Agency for Science, Technology and Research (A*STAR), the National Healthcare Group (NHG), whose mission is to nurture and support the translational development of biomedical technologies.

To quote our Co-inventor/Co-founder, Dr. Chun Yong Yao, “we can now access a strategic workspace with numerous networking opportunities for us to grow our company”.

Indeed, co11ab is physically located in Clinical Sciences Building, Lee Kong Chian School of Medicine, NTU, thus strategically within the HealthCity Novena where national health centres and public hospitals converge.

Co11ab also regularly organises events and networking sessions where we have been active as well.

We look forward to catching up with the community (special shoutout to our neighbour Skin Research Institute of Singapore (SRIS)) and forming deeper connections.

Photo courtesy of Co11ab.

From Left to Right: Chan Wen Kiat (CEO, Co-founder); Chun Yong Yao (Co-founder, Co-inventor); Diana Chor (General Manager)

13/07/2023

Thank you Centre for Medical Technologies and Innovations (CMTi) for this wonderful opportunity to feature Renectin Antiscar as one of National Skin Centre's innovative dermatological products as shared by Dr. Tey Hong Liang, Head of Research, NSC; Clinical Director, CMTi, NHG to 25th World Congress of Dermatology's delegates.

Photo courtesy of CMTi.

11/07/2023

Sounds bites from 25th World Congress of Dermatology!

Let's hear what Senior Consultant Dermatologist and Co-Inventor of Renectin Antiscar, Dr. Tey Hong Liang, has to say on scar prevention and how Renectin Antiscar compares with silicone gel sheet standard of care.

Interview dated 07 July 2023.

11/07/2023

We are so excited to be on Facebook to start connecting with YOU!

Firstly, let us introduce ourselves.

RNAscence Biotech is a start-up Company co-founded by A/Prof Timothy Tan, Dr. Chun Yong Yao and Mr. Wen Kiat Chan from Nanyang Technological University Singapore, Singapore (NTU).

Our first product, Renectin Antiscar, is developed as a result of years of research by Prof Tan and Dr Chun in RNA technology. This is also made possible with an important industry collaboration with National Skin Centre's Senior Consultant Dermatologist Prof. Tey Hong Liang in his professional capacity as a clinician.

We see Renectin Antiscar as the 1st breakthrough in 40 years of scar prevention and pioneering a class of its own : Active Scar Care.

A key unique feature that makes Renectin Antiscar stand out is its ability to target the root cause of scarring by delivering the active ingredient beneath the skin via dissolving microneedles.

We are grateful to have been given opportunities to share on our research & technology as well as Renectin Antiscar to clinicians and patients across Singapore. We also deeply appreciate the positive response that it has garnered from our adopters.

To learn more about us or Renectin Antiscar, please reach out via our LinkedIn or website RNAscence.com and we’ll be happy to connect with you.

Stay tuned for more updates on RNAscence Biotech as we journey on!

RNAscence Team Photo (Left to Right): A/Prof Timothy Tan (Co-founder, Co-inventor); Wen Kiat Chan (CEO, Co-founder); Chun Yong Yao (Co-founder, Co-inventor); Diana Chor (General Manager). Photo courtesy of Nanyang Technological University Singapore.